Team approach aims to boost cancer pill adherence and safety
NCT ID NCT01370980
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests a support program that brings together oncologists, pharmacists, doctors, and nurses to help cancer patients take their oral medications as prescribed. The goal is to improve treatment effectiveness and patient safety by ensuring better communication and follow-up. Adults 18 and older being treated for cancer with specific oral drugs can take part.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a support program involving oncologists, pharmacists, physicians, and nurses to improve medication adherence
- What this could lead to
- If successful, this approach could improve how well cancer patients follow their oral treatment plans and reduce complications.
- What could go wrong
- This is a small, early-stage study with only 43 participants, so results may not apply broadly. The program's success depends on many factors, including patient motivation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
43 people
The number who actually took part.
- Start date
-
Jul 2010
- Finished
-
Sep 2014
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with cancer treated by oral medication in swiss-romande hospitals and private oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years and older * Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox) * French speaking Exclusion Criteria: \- None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV
Lausanne, Canton of Vaud, 1010, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?